Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30298595 | 0.79 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CNAPRTPIK3CD | |
| SCHEMBL2780940 | 0.79 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CNAPRTPIK3CD | |
| SCHEMBL1783888 | 0.77 | CYP3A4 (0.43) | TDP1MAPK1CYP3A4TSHRTRPA1 | |
| SCHEMBL30520078 | 0.77 | CYP3A4 (0.43) | TDP1MAPK1CYP3A4TSHRTRPA1 | |
| SCHEMBL11955561 | 0.76 | — | — | |
| SCHEMBL17593401 | 0.76 | MAPK1 (0.43) | TDP1MAPK1CYP3A4TSHRTRPA1 | |
| SCHEMBL14323001 | 0.75 | CYP3A4 (0.42) | TDP1MAPK1CYP3A4TSHRTRPA1 | |
| SCHEMBL398915 | 0.75 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CTDP1MAPK1 | |
| SCHEMBL28631538 | 0.75 | CYP3A4 (0.42) | TDP1MAPK1CYP3A4TSHRTRPA1 | |
| SCHEMBL1191488 | 0.72 | CYP3A4 (0.39) | TDP1MAPK1CYP3A4TSHRTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919854-B2 | P2RX7 modulators in therapy | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2024-03-05 | — | — | US | disclosed |
| CN-112512520-B | P2RX7 modulators in therapy | 国家科学研究中心 | 2023-10-24 | — | — | CN | disclosed |
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3187490-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-04-06 | — | — | EP | disclosed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | disclosed |
| EP-3773557-A1 | P2RX7 MODULATORS IN THERAPY | Centre national de la recherche scientifique (FR) | 2021-02-17 | — | — | EP | disclosed |
| US-20210017131-A1 | P2RX7 MODULATORS IN THERAPY | JUNIA (FR) | 2021-01-21 | — | — | US | disclosed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | disclosed |
| WO-2019185868-A1 | P2RX7 MODULATORS IN THERAPY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-10-03 | — | — | WO | disclosed |
| EP-3515902-A1 | 6-MEMBERED CYCLIC AMINES OR LACTAMES SUBSTITUTED WITH UREA AND PHENYL | Grünenthal GmbH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2009097999-A1 | ARYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| CN-101203489-A | Oxindole derivatives | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | CN | disclosed |
| EP-1896412-A2 | OXINDOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136606-A2 | OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293319-A1 | Oxindole derivatives | LUK KIM-CHUN | 2006-12-28 | — | — | US | disclosed |
| US-4997667-A | Pyridinyl compounds of N-carbamoyl-N-thiocarbamoyl- or N-amidino-glycine or beta-alanine useful as sweetening agents | UNIVERSITE CLAUDE BERNARD (FR) | 1991-03-05 | — | — | US | disclosed |
| EP-0321368-A1 | Heterocyclic N-carbamoyl, N-thiocarbamoyl or N-amidino-aminomalonyl or -aminosuccinyl amide derivatives as sweetening agents | NOFRE, Claude (FR) | 1989-06-21 | — | — | EP | disclosed |
| EP-0321369-A1 | Heterocyclic sweeteners derived from N-carbamoyl-, N-thiocarbamoyl or N-amidino-glycine or beta-alanine | UNIVERSITE CLAUDE BERNARD - LYON 1 (FR) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017131-A1 | P2RX7 MODULATORS IN THERAPY | P2RX3, P2RX7, P2RX2 | ADRA2A 113/4885ADRA2B 102/4885ADRA2C 192/4885 |
| US-20060293319-A1 | Oxindole derivatives | CCNI, OGFR, MKI67 | ADRA2A 555/4885ADRA2B 594/4885ADRA2C 329/4885 |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | ADRA2A 81/4885ADRA2B 122/4885ADRA2C 133/4885 |
| US-11919854-B2 | P2RX7 modulators in therapy | P2RX7, P2RX2, P2RX1 | ADRA2A 124/4885ADRA2B 116/4885ADRA2C 215/4885 |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | ADRA2A 81/4885ADRA2B 122/4885ADRA2C 133/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | ADRA2A 81/4885ADRA2B 122/4885ADRA2C 133/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | ADRA2A 926/4885ADRA2B 958/4885ADRA2C 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.